US health technology assessor the Institute for Clinical and Economic Review (ICER) today released a Final Evidence Report ...

UK-based immunology specialist Allergy Therapeutics has announced that the Paul Ehrlich Institut (PEI) has granted a ...

USA-based XOMA Royalty Corporation (Nasdaq: XOMA) is to acquire Generation Bio (Nasdaq: GBIO) for around $4.29 per share.

In what was a busy day for Sanofi, the French pharma major has entered into a licensing and development collaboration with ...

US clinical-stage US autoimmune drug developer Kyverna Therapeutics saw its shares leap more than 23% to $10.82 after its ...

Dren Bio, a privately held, US clinical-stage biotechnology company developing first-in-class myeloid cell engager ...

US biotech Immunome has announced positive top-line results from the global pivotal Phase III RINGSIDE trial of varegacestat, ...

South Korea-based Lunit, a provider of AI for cancer diagnostics and precision oncology, has announced a deal with Japanese ...

UK based liquid medicines maker Rosemont Pharmaceuticals has appointed an American chief executive (CEO) as the business ...

UK-based Bicycle Therapeutics, a pharma company developing a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, has entered into a 15-year ...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the USA ...

The US Food and Drug Administration (FDA) yesterday removed a key limitation on the use of real-world evidence (RWE) used in ...